Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Coeptis expands license for CAR technology to autoimmune diseases

EditorRachael Rajan
Published 02/26/2024, 11:40 PM
Updated 02/26/2024, 11:40 PM
© Reuters.

WEXFORD, Pa. - Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP), a biopharmaceutical company, announced today an expansion of its exclusive license agreement with the University of Pittsburgh. The amendment includes autoimmune diseases in the development of its SNAP-CAR T and SNAP-CAR NK cell therapies, originally focused on oncology.

This strategic move leverages recent research suggesting the potential of CD19-targeting chimeric antigen receptor (CAR) T cells, initially used in B cell malignancies, to also address autoimmune diseases by targeting autoreactive B cells. The expansion aligns with a broader vision to explore revolutionary treatments for a range of autoimmune conditions such as systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed the company's dedication to developing these technologies for oncology and the immense potential they hold for the treatment of autoimmune diseases. The SNAP-CAR platform's adaptability to target multiple antigens could place Coeptis at the forefront of next-generation therapies.

The autoimmune disease market is significant, with more than 100 conditions affecting 1 in 5 Americans, predominantly women. The market is forecasted to grow substantially, from $7.68 billion in 2024 to $12.64 billion in 2028.

Coeptis Therapeutics is developing a portfolio of cell therapy platforms for cancer, autoimmune, and infectious diseases, featuring licensed assets from Deverra Therapeutics and the University of Pittsburgh, as well as collaborations with VyGen-Bio and the Karolinska Institutet.

The press release includes forward-looking statements involving risks and uncertainties, including the potential inability to realize the anticipated benefits of the licensed assets, the risks of clinical trial failures, and the impact of the global COVID-19 pandemic.

The information in this article is based on a press release statement from Coeptis Therapeutics.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.